Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
March 31, 2005
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
Conditions
Childhood Myelodysplastic Syndromesde Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRefractory AnemiaRefractory Anemia With Excess BlastsRefractory Anemia With Ringed SideroblastsRefractory Cytopenia With Multilineage DysplasiaSecondary Myelodysplastic SyndromesUnspecified Childhood Solid Tumor, Protocol Specific
Interventions
DRUG
lenalidomide
Given orally
Trial Locations (1)
91006-3776
COG Phase I Consortium, Arcadia
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00104962 - Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter